GlaxoSmithKline Pharmaceuticals Limited

NSE:GLAXO India Drug Manufacturers - General
Market Cap
$4.90 Billion
₹424.26 Billion INR
Market Cap Rank
#6601 Global
#234 in India
Share Price
₹2504.40
Change (1 day)
+0.74%
52-Week Range
₹2272.60 - ₹3466.20
All Time High
₹3466.20
About

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal disease… Read more

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2023: 0.024x

Based on the latest financial reports, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has a cash flow conversion efficiency ratio of 0.024x as of September 2023.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹362.20 Million) by net assets (₹15.40 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

GlaxoSmithKline Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how GlaxoSmithKline Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

GlaxoSmithKline Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GlaxoSmithKline Pharmaceuticals Limited ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for GlaxoSmithKline Pharmaceuticals Limited (2005–2025)

The table below shows the annual cash flow conversion efficiency of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 ₹19.51 Billion ₹12.90 Billion 0.661x +101.90%
2024-03-31 ₹17.78 Billion ₹5.82 Billion 0.327x +17.74%
2023-03-31 ₹17.41 Billion ₹4.84 Billion 0.278x -8.66%
2022-03-31 ₹26.63 Billion ₹8.11 Billion 0.304x -21.03%
2021-03-31 ₹14.99 Billion ₹5.78 Billion 0.386x +43.09%
2020-03-31 ₹18.21 Billion ₹4.90 Billion 0.269x +44.35%
2019-03-31 ₹21.40 Billion ₹3.99 Billion 0.187x -18.79%
2018-03-31 ₹20.57 Billion ₹4.73 Billion 0.230x +95.43%
2017-03-31 ₹20.07 Billion ₹2.36 Billion 0.118x +43.29%
2016-03-31 ₹16.96 Billion ₹1.39 Billion 0.082x -25.74%
2015-03-31 ₹24.44 Billion ₹2.70 Billion 0.111x -21.83%
2014-03-31 ₹19.90 Billion ₹2.81 Billion 0.141x -9.52%
2013-03-31 ₹20.07 Billion ₹3.14 Billion 0.156x -9.88%
2012-03-31 ₹19.36 Billion ₹3.36 Billion 0.173x -29.41%
2011-03-31 ₹19.52 Billion ₹4.79 Billion 0.246x -14.23%
2010-03-31 ₹17.86 Billion ₹5.12 Billion 0.286x +36.72%
2009-03-31 ₹15.76 Billion ₹3.30 Billion 0.209x -9.28%
2008-03-31 ₹13.81 Billion ₹3.19 Billion 0.231x +7.57%
2007-03-31 ₹12.05 Billion ₹2.59 Billion 0.215x -41.44%
2006-03-31 ₹9.53 Billion ₹3.49 Billion 0.367x +47.85%
2005-03-31 ₹9.24 Billion ₹2.29 Billion 0.248x --